Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer

Li-Yue Sun¹,²,³ | Wen-Jian Cen¹,²,³ | Wen-Ting Tang¹,²,³ | Ya-Kang Long¹,²,³ |
Xin-Hua Yang¹,²,³ | Xiao-Meng Ji¹,²,³ | Jiao-Jiao Yang¹,²,³ | Ren-Jing Zhang¹,²,³ |
Fang Wang¹,²,³ | Jian-Yong Shao¹,²,³ | Zi-Ming Du¹,²,³

¹State Key Laboratory of Oncology in South China, Guangzhou, China
²Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
³Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China

Correspondence
Jian-Yong Shao and Zi-Ming Du, Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong 510060, China. Email: shaojy@sysucc.org.cn (J.-Y. S.) and Email: duzm1@sysucc.org.cn (Z.-M. D.)

Abstract
Background: This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non-small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD-1/PD-L1 therapy) combined with chemotherapy or anti-angiogenesis therapy.

Methods: We conducted a retrospective analysis of NSCLC patients who underwent next-generation sequencing test (either 295-gene panel NGS or 1021-gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression-free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status.

Results: We enrolled 323 cases and 388 cases of NSCLC patients in the 295-gene panel cohort and 1021-gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti-angiogenesis therapy had longer PFS than other participants (p < 0.05).

Conclusions: The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.

Keywords
combination therapy, immune checkpoint inhibitor, non-small cell lung cancer, smoking, tumor mutational burden
1 | INTRODUCTION

Immune checkpoint inhibitors (ICIs) for programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockade have become one of the effective treatments for advanced non-small cell lung cancer (NSCLC). Tumor mutational burden (TMB) has been shown to predict the efficacy of ICI in the clinical studies of CheckMate 026 and CheckMate 227 in NSCLC, but it was controversial in KEYNOTE-021/041/042/044 studies. Therefore, the predictive value of TMB for ICI treatment in NSCLC still needs further investigation. In addition, due to the lack of standardized detection procedures of TMB, the definition of TMB high from different next-generation sequencing (NGS) platforms needs further clinical investigation and comparison as well.

Currently the combination of ICI with chemotherapy or anti-angiogenesis therapy has become a hotspot in the clinical treatment of advanced NSCLC. Some patients have benefited from such combination therapy, including the patients with low PD-L1 expression; however, the clinical efficacy prediction markers are lacking for such combination therapy. Further study is needed to determine if TMB could predict the clinical efficacy in NSCLC patients receiving ICI combined with chemotherapy or anti-angiogenesis therapy.

Smoking is well known as the primary cause of NSCLC. However, the correlation between smoking history and TMB is still contentious, and its role in efficacy prediction in ICI treatment of NSCLC needs additional study as well. One study showed that NSCLC patients who smoked could benefit more from second-line immunotherapy than non-smoking patients after resistance to first-line targeted therapy. Therefore, the relationship between smoking status and TMB, and the predictive value of combining smoking status with TMB for combination immunotherapy in NSCLC still needs further investigation.

In the present study, two advanced NSCLC cohorts from our hospital who received either 295-gene panel NGS test or 1021-gene panel NGS test (1021 cohort) at Sun Yatsen University Cancer Center from September 2017 to November 2020. The inclusion criteria included pathologically confirmed NSCLC, complete clinical information, and successful NGS detection. The Clinical Research Ethics Committee approved this study with ID: B2020-344-01. All procedures of this study were strictly following the Declaration of Helsinki (as revised in 2013).

2.2 | TMB detection

Tumor mutational burden value was calculated from the high-throughput sequencing data from both 295-gene panel and 1021-gene panel. The gene list for each panel is listed in Table S2 and S3. The NGS library preparation and sequencing protocol were performed as follows. In brief, the genomic DNA was fragmented by Covaris M220 focused ultrasonicator (Covaris, Inc.), converted to an NGS library by end repair, A-tailing, and adapter ligation. Then, DNA library was purified and quantified using Qubit 2.0 fluorimeter with the dsDNA high-sensitivity assay kit (Life Technologies). The samples tested with 295-gene panel were indexed and sequenced on Nextseq500 (Illumina, Inc.) and 1021-gene panel indexed samples were sequenced on Gene+Seq-2000 (Geneplus-Beijing Institute) with paired-end reads. In both 295-gene and 1021-gene panels, TMB was calculated by the number of somatic missense mutations, nonsense mutations, and coding indels and displayed as the number of mutations per Mb of captured genome. Fusions, copy number variations, and non-coding mutations were not counted. According to x-tile software, the optimal cut-off value used to define high TMB is 6.1 mutations/Mb in 295-gene panel and 15.4 mutations/Mb in 1021-gene panel, respectively.

2.3 | Follow-up

The clinical information of all patients was retrospectively obtained from their medical records. Treatment efficacy was evaluated according to the response evaluation criteria in solid tumors (RECIST) 1.1 criteria. The endpoint of follow-up was the last visit or disease progression after participants who received combination immunotherapy, and the end point of this study was progression-free survival (PFS).

2.4 | Statistical analysis

Statistical analysis was performed using the statistical software SPSS 20.0 (IBM Corp.). Measurement data were
expressed as means ± SD, and comparisons between groups were performed by t-test. A p < 0.05 was considered to be statistically significant. One-way ANOVA was used between the three groups of data, and p < 0.05 was considered to be statistically different. Kaplan–Meier analysis was used to estimate PFS after receiving combination therapy. GraphPad Prism 7.0 (GraphPad Software) was used for graphing.

3  |  RESULTS

3.1  |  Study population

This study enrolled 323 cases of NSCLC patients in the 295 cohort and 388 cases in the 1021 cohort. The characteristics of participants in the two cohorts are displayed in Table 1. Among them, there were 32 and 58 patients from 295 cohort and 1021 cohort, respectively, who received ICI combined with chemotherapy or anti-angiogenesis therapy (detailed information of these patients is shown in the Table S1).

3.2  |  Molecular characteristics

Driver gene variants including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1)/rearranged during transfection fusion, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E, and mesenchymal to epithelial transition factor (MET) amplification/exon 14 skipping mutations were more frequently found in non-smokers than that in smokers in both 295 cohort and 1021 cohort, respectively, who received ICI combined with chemotherapy or anti-angiogenesis therapy. GraphPad Prism 7.0 (GraphPad Software) was used for graphing.

3.3  |  Correlation between TMB and the smoking status

We then compared TMB data across two cohorts. In the 295 cohort, the average TMB values in all participants (323 cases), lung adenocarcinoma (LUAD, 272 cases), lung squamous cell carcinoma (LUSC, 45 cases), and adenosquamous carcinoma (ASQC, 6 cases), were 8.787 ± 7.732, 8.271 ± 7.320, 10.860 ± 8.502, and 16.670 ± 13.470 mutations/Mb, respectively. In the 1021 cohort, the TMB values in all participants (388 cases), LUAD (328 cases), LUSC (50 cases), and ASQC (10 cases) were 7.169 ± 6.855, 6.631 ± 6.815, 10.500 ± 6.489, and 8.544 ± 5.732 mutations/Mb, respectively (Figure 2).

The TMB value in smoking LUAD patients was significantly higher than that in non-smokers in both cohorts (295 cohort, 10.430 ± 7.468 mutations/Mb in 84 cases smoking patients vs. 6.452 ± 6.366 mutations/Mb in 154 cases non-smoking patients, p = 0.0002; 1021 cohort, 9.374 ± 8.479 mutations/Mb in 108 cases smoking patients vs. 5.010 ± 5.048 mutations/Mb in 201 cases non-smoking patients, p < 0.0001) (Figure 1A, B). However, there was no statistical TMB difference between smoking quiet and smoking in LUAD patients (295 cohort, 10.430 ± 7.468 mutations/Mb in 84 cases smoking patients vs. 8.105 ± 5.799 mutations/Mb in 18 cases smoking quiet patients, 10.430 ± 7.468 vs., p = 0.5796; 1021 cohort, 9.374 ± 8.479 mutations/Mb in 108 cases smoking patients vs. 7.418 ± 7.305 mutations/Mb in 20 cases smoking quiet patients, p = 0.6258) (Figure 1A,B). The TMB value of LUAD patients with a smoking index greater than 30 packs × years was significantly greater than that of non-smoking patients (Figure 2). Although the TMB value of smoking LUSC patients in the two cohorts was higher than that in non-smoking patients, the difference was not statistically significant (295 cohort, 11.950 ± 9.066 mutation/Mb in 35 cases smoking patients vs. 5.034 ± 3.094 mutations/Mb in 5 cases non-smoking patients, p = 0.3503; 1021 cohort, 9.374 ± 8.479 mutations/Mb in 33 cases smoking patients vs. 5.034 ± 3.094 mutations/Mb in 5 cases non-smoking patients, p = 0.2278) (Figure 1C, D).

Correlation analysis showed that in both 295 cohort and 1021 cohort, the smoking index and TMB were correlated (295 cohort, r² = 0.1095, p < 0.0001; 1021 cohort, r² = 0.1071, p < 0.0001). In LUAD, smoking index and TMB were correlated as well (295 cohort, r² = 0.0771, p < 0.0001; 1021 cohort, r² = 0.0884, p < 0.0001). However, in LUSC, the smoking index was not correlated with TMB (cohort 295, r² = 0.0547, p = 0.1464; cohort 1021, r² = 0.0588, p = 0.1086) (Figure 2).
Clinical outcomes

The median follow-up time of the 295 cohort and the 1021 cohort was 6.47 and 6.17 months, respectively. In the 295 cohort, the PFS of smoking patients was slightly longer than that of non-smoking patients, but the difference was not statistically significant (9.17 months in smoking patients vs. 6.00 months in non-smoking patients, \( p = 0.1070 \)). The PFS of patients with TMB high (TMB-H) was similar to that of patients with TMB low (TMB-L) (6.93 months in TMB-H vs. 7.77 months in TMB-L, \( p = 0.7030 \)). In the 1021 cohort, the PFS of non-smokers was slightly longer than that of smokers, but the difference was not statistically significant (9.03 months in smoking patients vs. 10.23 months in non-smoking patients, \( p = 0.1240 \)). Patients with TMB-H had a slightly longer PFS than patients with TMB-L, but the difference was not statistically significant as well (HR = 0.51 [0.22–1.19], \( p = 0.1714 \)) (Figure S3).

However, the PFS of patients with both TMB-H and smoking status was significantly longer than other patients, and the difference was statistically significant in both cohorts (295 cohort, 12.17 months in both TMB-H and smoking patients vs. 6.00 months in other patients, HR = 0.32 [0.12–0.89], \( p = 0.0071 \); 1021 cohort, HR = 0.29 [0.12–0.67], \( p = 0.0142 \)) (Figure 3A,B). Further stratification analysis showed that patients with TMB-H and no smoking had the shortest PFS in both cohorts (295 cohort, \( p = 0.0130 \); 1021 cohort, \( p < 0.0001 \)) (Figure 3C,D).

**DISCUSSION**

In the clinical treatment of advanced NSCLC, ICI targeting PD1/PD-L1 has made rapid progress.\(^\text{17}\) PD1/
PD-L1 inhibitor monotherapy or combination therapy with chemotherapy/antiangiogenic therapy has become one of the main treatment especially for NSCLC patients without the presence of driver gene mutation. However, currently there is no effective biomarkers for the efficacy prediction of combination immunotherapy, and the relationship between TMB and smoking status in NSCLC is controversial. In this study, we retrospectively recruited 711 cases NSCLC patients who received two different NGS panel tests to analyze the relationship between TMB and smoking status, and we further evaluated the efficacy predictive value of smoking status and TMB in 90 cases NSCLC patients who received ICI therapy combined with chemotherapy/anti-angiogenesis therapy.

Tumor mutational burden as a predictive marker of ICI efficacy is controversial in multiple studies, moreover, there is a lack of evidence for its application in ICI combination therapy. Chen et al. found that TMB could not predict treatment efficacy in advanced NSCLC patients treated with camrelizumab combined with apatinib. Another study showed that TMB could not predict the efficacy of sintilimab combined with dual-drug chemotherapy. In addition, the definition of high TMB measured by different NGS detection platforms (different gene panels) might be different. Our results also found in the two different patients cohorts that TMB alone could not predict the prognosis of advanced NSCLC patients receiving ICI combination therapy in both cohorts.

Smoking NSCLC patients may carry more gene mutations, especially TP53, KRAS, and PIK3. Therefore, the TMB value in smoking patients is supposed to be increased. However, the correlation between the smoking index and the TMB value of NSCLC patients is still controversial. Previous studies have shown that smoking patients receiving ICI monotherapy have better response rates and PFS than non-smokers, but there is no difference in overall survival between two groups. In ICI combined chemotherapy/anti-angiogenesis therapy, it has also been shown that both smokers and non-smokers could benefit from combination therapy compared to chemotherapy alone. Another study also showed that in patients with PD-L1 expression ≥50%, non-smokers had shorter PFS than heavy-smokers, but the difference was not statistically significant. Our study also found that TP53, KRAS, and PIK3 gene mutations in smoking patients were increased compared with non-smoking patients. In the two cohorts, the TMB value in...
LUAD was correlated with the smoking index (295 cohort, $r^2 = 0.0771, p < 0.0001$; 1021 cohort, $r^2 = 0.0884, p < 0.0001$). However, the TMB value of LUSC has nothing to do with the smoking index. Our results also found that smoking status alone cannot predict the prognosis of NSCLC patients treated with ICI combination therapy. Taken together, our results showed that neither TMB alone nor smoking status alone could predict the efficacy of ICI combination therapy in advanced NSCLC.

Next, we speculated that combining the two indicators may predict the efficacy of ICI combination therapy. After combining TMB value with smoking status, we found that TMB-H/smoking patients had much better PFS than other patients in both 295 cohort and 1021 cohort, suggesting that TMB combined with smoking status might be an efficient predictor of NSCLC patients receiving ICI combination therapy. Meanwhile the PFS of TMB-H/non-smoking patients was the shortest in both cohorts, suggesting that these patients may have different resistance mechanisms of ICI combination therapy.

Interestingly, the PFS of TMB-L/non-smoking patients and TMB-H/smoking patients was quite similar, and the difference was not statistically significant (295 cohort, $p = 0.5608$; 1021 cohort, $p = 0.0549$). Previous study has found that patients with low TMB have better efficacy than those with moderate TMB after receiving ICI treatment. This suggests that the role of TMB in predicting the efficacy of ICI may not be a purely linear relationship, and further research is needed to elucidate its role in ICI combination therapy.

Although our study found that TMB combined with smoking status was a potential predictor of efficacy in advanced NSCLC patients receiving ICI combination therapy, the study had the following shortcomings: (1) The sample size in this study was small, which may lead to bias; (2) About 10% of patients had driver gene mutations; and 3. Different ICI (different PD-1 antibodies or PD-L1 antibodies) and combination therapy (chemotherapy and/or anti-angiogenesis therapy) included in this study, and the potential different effects of such drugs cannot be ruled out.

5 | CONCLUSIONS

This study retrospectively analyzed advanced NSCLC patients receiving ICI combined with chemotherapy/anti-angiogenesis therapy in two different NGS detection cohorts. The TMB value correlated with smoking status
in LUAD patients, but not in LUSC patients. The results showed that TMB value combined with smoking status could be used as a potential prognostic indicator for advanced NSCLC patients receiving ICI combination therapy. This study provided a potential prognostic indicator for the personalized immunootherapy of advanced NSCLC.

AUTHOR CONTRIBUTIONS
Conceptualization, Li-Yue Sun, Zi-Ming Du, and Jian-Yong Shao; methodology, Li-Yue Sun, Zi-Ming Du, and Xin-Hua Yang; validation, Li-Yue Sun, Wen-Jian Cen, Wen-Ting Tang, and Ya-Kong Long; formal analysis, Xin-Hua Yang and Xiao-Meng Ji; investigation, Li-Yue Sun and Zi-Ming Du; resources, Fang Wang and Jian-Yong Shao; data curation, Wen-Jian Cen, Wen-Ting Tang, Jiao-Jiao Yang, and Ren-Jing Zhang; writing—original draft preparation, Li-Yue Sun; writing—review and editing, Zi-Ming Du; supervision, Jian-Yong Shao; project administration, Zi-Ming Du; All authors have read and agreed to the published version of the manuscript.

CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.

ETHICAL STATEMENT
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The present study was approved by the Clinical Research Ethics Committee of Sun Yat-sen University Cancer Center (no. B2020-344–01). All procedures were strictly in accordance with the appropriate version of the Declaration of Helsinki (as revised in Brazil 2013). Individual consent for this retrospective analysis was waived.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Li-Yue Sun https://orcid.org/0000-0003-1919-0820

REFERENCES
1. Melosky B, Juergens R, McLeod D, et al. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 2019;134:259-267.
2. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. *N Engl J Med*. 2017;376(25):2415-2426.

3. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med*. 2018;378(22):2093-2104.

4. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol*. 2016;17(11):1497-1508.

5. Chung HC, Ros W, Delord J-P, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol*. 2019;37(17):1470-1478.

6. Garassino MC, Gadgeel S, Esteban E, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2020;21(3):387-397.

7. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051.

8. Qiu L, Zhao X, Shi W, et al. Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. *Medicine (Baltimore)*. 2020;99(24):e20545.

9. Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. *Oncoologist*. 2019;24(Suppl 1):S31-S41.

10. Tartrarone A, Lerose R, Aieta M. Focus on lung cancer screening. *J Thorac Dis*. 2020;12(7):3815-3820.

11. Sharpnack MF, Cho JH, Johnson TS, et al. Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer. *Lung Cancer*. 2020;146:36-41.

12. Gainor JF, Rizvi H, Jimenez Aguilar E, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. *Ann Oncol*. 2020;31(3):404-411.

13. Garassino MC, Gelibter AJ, Grossi F, et al. Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients. *J Thorac Oncol*. 2018;13(8):1146-1155.

14. Jiao X-D, Zhang X-C, Qin B-D, et al. Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. *Ann Transl Med*. 2020;8(14):860.

15. Chen Y, Li X, Liu G, et al. Association of tumor protein p53 and ataxia-telangiectasia mutated comutation with response to immune checkpoint inhibitors and mortality in patients with non-small cell lung cancer. *JAMA Netw Open*. 2019;2(9):e1911895.

16. Camp RL, Doller-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcomes-based cut-point optimization. *Clin Cancer Res*. 2004;10(21):7252-7259.

17. Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). *Expert Opin Investig Drugs*. 2020;29(12):1355-1364.

18. Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treat Rev*. 2019;75:39-51.

19. Chiu M, Lipka MB, Bhatje P, Fu P, Dowlati A. A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. *Transl Lung Cancer Res*. 2020;9(1):55-60.

20. Chen Y, Li X, Liu G, et al. ctDNA concentration, MIKI67 mutations and hyper-progressive disease related gene mutations are prognostic markers for camrelizumab and apatinib combined multilime treatment in advanced NSCLC. *Front Oncol*. 2020;10:1706.

21. Jiang H, Zheng Y, Qian J, et al. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. *Cancer Immunol Immunother*. 2021;70(3):857-868.

22. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. *J Immunother Cancer*. 2020;8(1).

23. Jacob A, Wu J, Kolesar J, et al. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: analysis from Kentucky Cancer Registry. *Cancer Med*. 2021;10(6):2054-2062.

24. Wang X, Ricciuti B, Nguyen T, et al. Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. *Cancer Res*. 2021;81(9):2566-2573.

25. Yuan S, Xia Y, Shen L, et al. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody. *Cancer Immunol Immunother*. 2021;70(2):533-546.

26. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy for metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;379(22):2078-2092.

27. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(7):924-937.

28. Nie W, Xu M-D, Gan LU, et al. Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from immunotherapy. *J Immunother*. 2020;43(6):189-195.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Sun L-Y, Cen W-J, Tang W-T, et al. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immunotherapy with programmed cell death 1 blockade in non-small cell lung cancer. *Cancer Med*. 2021;10:6610–6617. [https://doi.org/10.1002/cam4.4197](https://doi.org/10.1002/cam4.4197)